|Dr Smitha Georgy is in the CCS Epidermal/Development lab|
HNSCC is the sixth most prevalent cancer world-wide, with 600,000 new cases reported annually. The current conventional treatment regimens (surgery, radiation, and chemotherapy) are non-selective, and are administered regardless of the etiology or molecular drivers. We have recently made a major contribution towards understanding the molecular drivers of HNSCC with the identification of a novel GRHL3/GSK3B/c-MYC proto-oncogenic network that is activated in these cancers. The establishment of orthotopic mice model in the laboratory provides an excellent tool to identify selective inhibitors in HNSCC. The objectives of the proposed research are to analyse the signalling pathways in HNSCC and to identify the appropriate combination therapy in metastatic HNSCC.
- Research group: www.med.monash.edu.au/medicine/alfred/research/epidermal-development.html
- Recent publications: